HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
INSIDE INDUSTRY
PharmaCell to acquire cell therapy production facility from TiGenix
PharmaCell B.V. a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its state-of-the-art cell therapy production facility at the Chemelot site in Sittard-Geleen, close to Maastricht (The Netherlands). TiGenix is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®.

TiGenix and PharmaCell have signed an agreement to purchase the shares of TiGenix B.V., which holds the manufacturing site. PharmaCell will acquire the facility, including its qualified team of employees in Production, QC, QA and other functions. ChondroCelect® will continue to be manufactured at the facility as before under a long-term CMO agreement with PharmaCell.

In 2012, TiGenix's state-of-the-art manufacturing facility in Sittard-Geleen, the Netherlands, successfully passed cGMP inspection by the Dutch authorities, and obtained approval from the European Medicines Agency for the production of ChondroCelect®, the company's commercial cell therapy product for cartilage repair in the knee. Going forward, PharmaCell intends to produce other commercial and investigational cell therapy and regenerative medicine products at the site.

Alexander Vos, CEO of PharmaCell B.V. said, "The new partnership with TiGenix is a further step forward to strengthen our business in support of the development of the cell therapy industry in Europe. PharmaCell and TiGenix have created a collaborative business model for cell therapeutics in general and for ChondroCelect® in particular."

Source: B3C Newswire

Click here for the complete issue.

NEWS CRUNCH  
news Genetically boosting the nutritional value of corn could benefit millions
news Inhibitor Pariet obtained approval of additional dosage in Japan for maintenance therapy of proton pump inhibitor resistant reflux esophagitis
news Dornier MedTech opens Asia Pacific Headquarters & Global Clinical Innovation Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy